Development Pipeline

Chugai’s development pipeline is categorized to Oncology, Autoimmune Diseases, Neurology, and Other diseases.
View the status of our current development pipeline as of Oct 22, 2021 in a PDF format.

Development Pipeline (all disease areas) [PDF 274KB]

Basic Information on Development Pipeline*
*Exclude products that have already obtained regulatory approval

Oncology

Origin
(Collaborator)
Modality Generic name, Development Code, Mode of Action Indication Basic Information
Roche small molecule ipatasertib/RG7440
AKT inhibitor
Prostate cancer RG7440 is an AKT inhibitor in-licensed from Roche.
Roche antibody tiragolumab/RG6058
Anti-TIGIT human monoclonal antibody
SCLC
NSCLC
NSCLC (stage III)
Esophageal cancer
RG6058 is an anti-TIGIT monoclonal antibody in-licensed from Roche. TIGIT is an immune checkpoint expressed on the surface of NK cells and T cells that binds to poliovirus receptors (PVR) expressed on tumor cell surfaces. This binding is thought to allow the cancer cells to evade attack by immune cells. RG6058 restores and maintains the immune response of NK cells and T cells by blocking the binding of TIGIT to PVR, and is thus expected to demonstrate efficacy against cancer cells.
Roche small molecule giredestrant/RG6171
Selective Estrogen Receptor Degrader (SERD)
Breast cancer
Breast cancer (adjuvant)
RG6171 is a selective estrogen receptor degrader (SERD) in-licensed from Roche. It is expected to exert a stronger anti-estrogen effect by promoting the degradation of ER as well as competitively inhibiting estrogen receptor binding.
In-house antibody codrituzumab
Anti-Glypican-3 humanized monoclonal antibody
HCC GC33, a humanized monoclonal antibody created by Chugai, targets glypican-3 (GPC3), which is specifically expressed in hepatocellular carcinoma.
In-house antibody ERY974
Anti-Glypican-3/CD3 bispecific antibody
Solid tumors ERY974 is the first T-cell redirecting antibody (TRAB) developed by Chugai. TRAB is a bispecific antibody that creates a short bridge between CD3 on T cells and tumor antigen on tumor cells to activate T cells in a tumor antigen-dependent manner, and is expected to demonstrate strong cytotoxicity against tumor cells.
Roche small molecule cobimetinib/ RG7421
MEK inhibitor
Solid tumors RG7421 is an MEK inhibitor in-licensed from Roche.
Roche antibody cibisatamab/RG7802
Anti-CEA/CD3 bispecific antibody
Solid tumors RG7802, a bispecific antibody in-licensed from Roche, is expected to activate T cells and attack tumor cells by crosslinking CD3 on T-cells to carcinoembryonic antigen (CEA) on tumor cells.
Roche antibody mosunetuzumab/RG7828
Anti-CD20/CD3 bispecific antibody
Hematologic tumors RG7828 is a bispecific antibody in-licensed from Roche. It is expected to activate T cells and attack tumor cells by crosslinking CD3 on T cells to CD20 on B cells.
Roche antibody glofitamab/RG6026
Anti-CD20/CD3 bispecific antibody
Hematologic tumors RG6026 is a bispecific antibody in-licensed from Roche. By cross-linking CD3 on T cells with CD20 on B cells, it is expected to cause T-cell activation and proliferation and attack on the target B cells through cytokine release, resulting in antitumor effect.
In-house antibody AMY109
Solid tumors AMY109 is the third therapeutic antibody to apply the recycling antibody engineering technology created by Chugai.
In-house antibody STA551
Anti-CD137 agonistic Switch antibody
Solid tumors STA551, a “switch antibody,” is the first application of switch antibody technology, which was developed by Chugai. Switch antibodies bind to the target antigen only where there is a high concentration of a certain “switch” molecule, which is concentrated specifically at the diseased site. STA551 binds to CD137 and activates T cells in the presence of the switch molecule ATP, but not in the absence of ATP. It therefore promises to act selectively on tumors.
In-house small molecule SPYK04
-
Solid tumors SPYK04 is a small molecule drug developed in-house by Chugai.
Roche antibody RG6194
Anti-HER2/CD3 bispecific antibody
Solid tumors RG6194, an anti-HER2/CD3 bispecific antibody in-licensed from Roche, is expected to act against HER2-expressing cancer cells by inducing and activating T cells.
In-house
(licensed out to Roche)
antibody SOF10/RG6440
Anti-latent TGF-β1 monoclonal antibody
Solid tumors SOF10, a monoclonal antibody created by Chugai, binds to latent TGF-β1 and inhibit the activation. By changing the immunosuppressive tumor microenvironment, such as developing fibrosis of tumor tissue, an anti-tumor effect is expected against cancers where anti-cancer drugs do not respond.
Roche small molecule pralsetinib/RG6396
RET inhibitor
Solid tumors RG6396 is a RET inhibitor designed to selectively target rearranged during transfection (RET) alterations, including fusions and mutations, regardless of the tissue of origin.
In-house mid-size molecule LUNA18
RAS inhibitor
Solid tumors LUNA18, the first project in mid-size molecule drug project, is an orally administrable cyclic peptide molecule created by Chugai’s unique APOLLO* platform. It inhibits protein-protein interaction between RAS and GEF to retain RAS in an inactive state. LUNA18 exhibits growth inhibitory activity against tumor cells with various RAS alterations (mutations or amplifications) and can be expected to have anti-tumor effects against cancers with RAS alterations where there are no therapeutic drugs yet.
  • *APOLLO: Artificial, Peptidic, Orally available, Limitlessly Localizable Omicron
In-house
(licensed out to 3rd party)
small molecule CKI27
RAF/MEK inhibitor
Ovarian cancer
NSCLC
CKI27 is an oral RAF/MEK inhibitor developed in-house by Chugai.
In January 2020, Chugai granted Verastem Oncology an exclusive worldwide license to manufacture, develop and commercialize CKI27.

Autoimmune Diseases

Origin
(Collaborator)
Modality Generic name, Development Code, Mode of Action Indication Basic Information
Roche non-antibody protein efmarodocokin alfa/RG7880
Human IL-22 fusion protein
Inflammatory bowel disease RG7880 is a human IL-22 fusion protein in-licensed from Roche. It is expected to demonstrate efficacy in treating inflammatory bowel disease by directly promoting the regenerative and protective functions of IL-22 in epithelial tissue.

Neurology

Origin
(Collaborator)
Modality Generic name, Development Code, Mode of Action Indication Basic Information
Roche antibody gantenerumab/RG1450
Anti-amyloid-beta human monoclonal antibody
Alzheimer’s disease RG1450 targets aggregate amyloid beta, with a high binding affinity to plaques in particular. It is expected to reduce cognitive deterioration by removing amyloid beta in the brain.
Roche nucleic acid tominersen/RG6042
Antisense oligonucleotide targeting HTT mRNA
Huntington’s disease RG6042 is an ASO targeting human HTT mRNA, which is believed to be the cause of Huntington’s disease. It has the potential to delay or slow disease progression in people with Huntington’s disease by binding specifically to HTT mRNA, after which synthesis of the HTT protein is inhibited.
Roche small molecule ralmitaront /RG7906
Partial TAAR1 agonist
Schizophrenia RG7906 has the novel pharmacological action of working as a partial agonist of trace amino-associated receptor Type 1 (TAAR1).
Roche antibody prasinezumab/RG7935
Anti-α-synuclein monoclonal antibody
Parkinson’s disease RG7935 is a monoclonal antibody that targets α-synuclein. It slows the expansion of nerve cell death by inhibiting the cell-to-cell propagation of aggregated forms of neurotoxic α-synuclein, and is expected to reduce and delay progression of the disease.
In-house (licensed out to Roche) antibody GYM329/RG6237
Anti-latent myostatin sweeping antibody
Neuromuscular disease GYM329, created by Chugai, is a next-generation antibody that applies Chugai’s proprietary antibody engineering technologies, including its recycling antibody and sweeping antibody technologies. Latent myostatin is an inactive form that is mainly secreted from muscle cells, and is activated by BMP-1 and other protein degrading enzymes. Activated myostatin inhibits muscle growth and hypertrophy, and by inhibiting myostatin, GYM329 is expected to improve the various conditions associated with muscle atrophy and loss of muscular strength.
Roche antibody semorinemab/RG6100
Anti-tau humanized monoclonal antibody
Alzheimer’s disease RG6100 binds to tau proteins found in the extracellular space of the brain, and is expected to slow the deterioration of cognitive functions in Alzheimer’s disease by halting the propagation of tau via neurons.
Roche antibody RG6102
Anti-amyloid beta/TfR1 fusion protein
Alzheimer’s disease RG6102 is gantenerumab (RG1450) with a novel transferrin receptor (TfR1) binding Ab moiety to achieve efficient transport over the BBB and target Aβ engagement in the brain. It is potential for superior Aβ clearance in brain to delay progression of Alzheimer’s disease.

Other diseases

Origin
(Collaborator)
Modality Generic name, Development Code, Mode of Action Indication Basic Information
Roche antibody faricimab/ RG7716
Anti-VEGF/Ang2 bispecific antibody
Diabetic macular edema Neovascular age related macular degeneration (nAMD)
Retinal vein occlusion
RG7716, which Chugai in-licensed from Roche, is the first bispecific antibody for ophthalmology diseases. It selectively binds to vascular endothelial growth factor A (VEGF-A), a key mediator of angiogenesis and vascular permeability, and angiopoietin-2 (Ang-2, an antagonist of Ang-1, which contributes to the stability of mature vessels), a destabilizer of chorioretinal vessels and inducer of vascular permeability. By simultaneously neutralizing intraocular VEGF-A and Ang-2 in wAMD and DME patients, RG7716 is expected to demonstrate better treatment outcomes and a more sustained effect than the anti-VEGF drugs that are the current standard of care.
In-house (licensed out to Roche) antibody crovalimab (SKY59)/RG6107
Anti-C5 recycling antibody
Paroxysmal nocturnal hemoglobinuria (PNH) SKY59 is a recycling antibody discovered by Chugai that inhibits the C5 complement component. The onset of a number of diseases is reported to be caused by complement activation. SKY59 is expected to inhibit cleavage of C5 to C5a and C5b, thus suppressing complement activation and improving disease conditions. In PNH, SKY59 may have a suppressive effect on hemolysis by preventing the destruction of red blood cells. Application of multiple Chugai proprietary antibody engineering technologies resulted in a prolonged half-life, and the antibody is being developed as a subcutaneous self-injection.
In-house antibody NXT007
Anti-coagulation factor IXa/X bispecific antibody
Hemophilia A NXT007, created by Chugai, is a bispecific antibody that stimulates blood coagulation using the same mode of action as Hemlibra. It is applied with Chugai’s antibody engineering technologies FAST-Ig, which enhances large-scale production of the bispecific antibody and ACT-Fc, which is expected to improve antibody pharmacokinetics. NXT007 is expected to achieve the levels of hemostasis found in healthy adults and children, and is being developed to improve convenience, including the administration device.
In-house small molecule PCO371
PTH1 receptor agonist
Hypoparathyroidism PCO371 is an oral PTH1 receptor agonist for hypoparathyroidism developed in-house by Chugai.
In-house antibody AMY109
-
Endometriosis AMY109 is the third therapeutic antibody to apply the recycling antibody engineering technology created by Chugai. Its approach differs from hormone therapy, which is the standard treatment for endometriosis, and its anti-inflammatory action is expected to provide new value to patients.
Roche antibody RG7992
Anti-FGFR1/KLB bispecific antibody
Non-alcoholic steatohepatitis (NASH) RG7992 is an anti-FGFR1/KLB bispecific antibody designed to mimic the metabolic hormone FGF21.
In-house (licensed out to 3rd party) antibody nemolizumab/CIM331
Anti-IL-31 receptor A humanized monoclonal antibody
Atopic dermatitis
Prurigo nodularis
CIM331 (nemolizumab) is an anti-IL-31 receptor A humanized monoclonal antibody originating from Chugai. The drug is expected to improve itching and skin inflammation in atopic dermatitis by blocking IL-31, a proinflammatory cytokine, from binding to its receptor.
In July 2016, Chugai entered into a global license agreement granting Galderma S.A. of Switzerland exclusive rights for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan. In September 2016, Chugai entered into a license agreement granting Maruho Co., Ltd., the rights for the development and marketing of nemolizumab in the skin disease area for the Japanese market.
In-house (licensed out to 3rd party) small molecule OWL833
Oral non-peptidic GLP-1 receptor agonist
Type 2 diabetes OWL833 is an oral non-peptidic GLP-1 receptor agonist created by Chugai. GLP-1 agonists have potent hypoglycemic action and induce weight loss, but convenience for patients has been an issue because they are conventionally administered in a subcutaneous injection. Because OWL833 is orally bioavailable, it is easier for patients to take, and is thus expected to contribute to the treatment of diabetes, including through improvement of drug adherence.
In September 2018, Chugai licensed the worldwide development and commercialization rights for OWL833 to Eli Lilly and Company.
  • Like
  • Tweet
  • LINE it!
  • E-mail

Main Products / Development Pipeline

Back to top